drugset / Trial / NCT02363439
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
NaSingle-groupOpen-labelTreatment
Summary
An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.
Timeline
- Start
- 2014-11
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAZLITORAN | Oligonucleotide (other) | 0.6 mg/kg | Subcutaneous |
| Subject | BAZLITORAN | Oligonucleotide (other) | 1.2 mg/kg | Subcutaneous |